Women's health


HBM contact: Dr Ivo Staijen, Dr Chandra Leo

Company status: public

ObsEva is a biopharmaceutical company addressing important unmet needs in women’s health, including premature labor, infertility and endometriosis. ObsEva’s pipeline comprises a number of orally active small molecules addressing both validated and novel targets. 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171